ProKidney (PROK) Stock Price, News & Analysis

Company Overview

ProKidney, Inc. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.

ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products. These candidates are designed to mitigate inflammatory responses, promote tissue repair and reduce the progression of kidney damage in hospitalized patients at risk of AKI, including those undergoing major surgery or experiencing sepsis. In addition to its clinical-stage portfolio, the company maintains preclinical efforts exploring broader applications in CKD and related nephrology indications.

Founded in 2015 and headquartered in Massachusetts, ProKidney completed its initial public offering in 2022, trading on the NASDAQ under the ticker PROK. The management team comprises professionals with expertise in nephrology research, cell therapy manufacturing and clinical development. ProKidney conducts its clinical trials predominantly in the United States, collaborating with academic medical centers and specialized contract research organizations to advance its pipeline toward regulatory milestones.

Key Stats

• Today's Range: $1.72 to $1.87
• 50-Day Range: $1.55 to $2.18
• 52-Week Range: $0.54 to $7.13
• Volume: 803,307 shs
• Average Volume: 896,618 shs
• Market Capitalization: $543.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.40
• Consensus Rating: Moderate Buy

ProKidney Stock Analysis - MarketRank™

ProKidney scored higher than 49% of companies evaluated by MarketBeat, and ranked 464th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

ProKidney has a consensus price target of $7.40, representing about 325.3% upside from its current price of $1.74.

Amount of Analyst Coverage

ProKidney has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ProKidney are expected to decrease in the coming year, from ($0.49) to ($0.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProKidney is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProKidney is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.92% of the float of ProKidney has been sold short.

Short Interest Ratio / Days to Cover

ProKidney has a short interest ratio ("days to cover") of 18.45, which indicates bearish sentiment.

Change versus previous month

Short interest in ProKidney has recently decreased by 6.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProKidney does not currently pay a dividend.

Dividend Growth

ProKidney does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

ProKidney has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ProKidney insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.83% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/23/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PROK
• CIK: 1850270
• Web: www.prokidney.com
• Phone: 336-999-7028
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ProKidney: $7.40
• High Price Target: $12.00
• Low Price Target: $1.00
• Potential Upside/Downside: +311.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$68.99 million
• Net Margins: -8,131.50%
• Pretax Margin: -17,599.32%
• Return on Equity: N/A
• Return on Assets: -21.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.06
• Quick Ratio: 9.06

Sales & Book Value

• Annual Sales: $890 thousand
• Price / Sales: 610.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.36) per share
• Price / Book: -0.54

Miscellaneous

• Outstanding Shares: 302,060,000
• Free Float: 181,750,000
• Market Cap: $543.71 million
• Optionable: Optionable
• Beta: 1.65